NF2 (Merlin) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Renal cell carcinoma, Breast cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Probable regulator of the Hippo/SWH (Sav/Wts/Hpo) signalling pathway, a signalling pathway that plays a pivotal role in tumour suppression by restricting proliferation and promoting apoptosis. Along with WWC1 can synergistically induce the phosphorylation of LATS1 and LATS2 and can probably function in the regulation of the Hippo/SWH (Sav/Wts/Hpo) signalling pathway. May act as a membrane stabilising protein. May inhibit PI3 kinase by binding to AGAP2 and impairing its stimulating activity. Suppresses cell proliferation and tumorigenesis by inhibiting the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex. Location: Cell projection, filopodium membrane; Cell projection, ruffle membrane; Nucleus; Cytoplasm, perinuclear region (UniProt). Locus 22q12.2 (HGNC).
- Mesothelioma: Open Targets association 0.59 with malignant mesothelioma (MONDO_0006292); IntOGen driver in 4 cohorts (PLMESO)
- Renal cell carcinoma: Open Targets association 0.59 with renal cell carcinoma (MONDO_0005086); IntOGen driver in 3 cohorts (CCRCC, PRCC, RCC)
- Breast cancer: Open Targets association 0.50 with breast cancer (MONDO_0007254); CIViC evidence names this disease
- Thyroid cancer: CIViC evidence names this disease
- Ovarian cancer: Open Targets association 0.55 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT)
- Cervical cancer: IntOGen driver in 1 cohort (CESC)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"NF2" OR ABSTRACT:"NF2" OR TITLE:"NF2, moesin-ezrin-radixin like MERLIN tumor suppressor" OR ABSTRACT:"NF2, moesin-ezrin-radixin like MERLIN tumor suppressor" OR TITLE:"Merlin" OR ABSTRACT:"Merlin" OR TITLE:"merlin" OR ABSTRACT:"merlin" OR TITLE:"merlin-1" OR ABSTRACT:"merlin-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NF2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/nf2.json. Licence CC BY-NC 4.0.